TG Therapeutics (TGTX) Financials

$39.54 +1.55 (+4.09%)

Closing price 04/23/2025 03:58 PM Eastern

Extended Trading

$39.33 -0.22 (-0.55%)

As of 08:17 AM Eastern

Annual Income Statements for TG Therapeutics

This table shows TG Therapeutics' income and expenses over time, based on annual financial data. All values are USD millions unless otherwise specified.

Metric	2015	2016	2017	2018	2019	2020	2021	2022	2023	2024
Net Income / (Loss) Attributable to Common Shareholders	-63	-78	-118	-173	-173	-279	-348	-224	13	23
Consolidated Net Income / (Loss)	-63	-78	-118	-173	-173	-279	-348	-224	13	23
Net Income / (Loss) Continuing Operations	-63	-78	-118	-173	-173	-279	-348	-224	13	23
Total Pre-Tax Income	-63	-78	-118	-173	-173	-279	-348	-224	13	26
Total Operating Income	-63	-79	-119	-174	-169	-274	-345	-218	21	42
Total Gross Profit	0.15	0.15	0.15	0.15	0.15	0.15	5.90	2.79	220	291
Total Revenue	0.15	0.15	0.15	0.15	0.15	0.15	6.69	2.79	234	329
Operating Revenue	0.15	0.15	0.15	0.15	0.15	0.15	6.69	2.79	234	329
Total Cost of Revenue	0.00	0.00	0.00	0.00	0.00	0.00	0.79	0.00	14	38
Operating Cost of Revenue	-	-	-	-	0.00	0.00	0.79	-	14	38
Total Operating Expenses	63	79	119	175	169	274	351	221	199	249
Selling, General & Admin Expense	16	9.89	16	15	15	108	128	95	123	154
Research & Development Expense	48	69	103	159	154	166	223	125	76	94
Total Other Income / (Expense), net	0.23	0.72	0.24	0.92	-3.82	-5.79	-3.33	-5.50	-7.57	-16
Interest Expense	-	-	0.85	0.88	5.29	6.33	5.64	10	13	24
Other Income / (Expense), net	0.06	0.39	1.08	1.80	1.47	0.54	2.31	4.70	5.04	7.69
Income Tax Expense	-	-	-	-	-	-	0.00	0.00	0.39	2.21
Basic Earnings per Share	($1.38)	($1.60)	($1.91)	($2.30)	($1.96)	($2.42)	($2.63)	($1.65)	$0.09	$0.16
Weighted Average Basic Shares Outstanding	45.65M	49.04M	62.07M	75.47M	88.37M	115.33M	132.22M	135.41M	141.96M	145.32M
Diluted Earnings per Share	($1.38)	($1.60)	($1.91)	($2.30)	($1.96)	($2.42)	($2.63)	($1.65)	$0.09	$0.15
Weighted Average Diluted Shares Outstanding	45.65M	49.04M	62.07M	75.47M	88.37M	115.33M	132.22M	135.41M	148.51M	160.34M
Weighted Average Basic & Diluted Shares Outstanding	45.65M	49.04M	62.07M	75.47M	88.37M	115.33M	132.22M	146.36M	154.42M	157.07M

This table shows TG Therapeutics' income and expenses over time, based on quarterly financial data. All values are USD millions unless otherwise specified.

Metric	Q3 2022	Q4 2022	Q1 2023	Q2 2023	Q3 2023	Q4 2023	Q1 2024	Q2 2024	Q3 2024	Q4 2024
Net Income / (Loss) Attributable to Common Shareholders	-36	-78	-39	-48	114	-14	-11	6.88	3.88	23
Consolidated Net Income / (Loss)	-36	-78	-39	-48	114	-14	-11	6.88	3.88	23
Net Income / (Loss) Continuing Operations	-36	-78	-39	-48	114	-14	-11	6.88	3.88	23
Total Pre-Tax Income	-36	-78	-39	-48	114	-14	-11	6.55	4.27	25
Total Operating Income	-35	-78	-37	-45	115	-12	-9.27	8.82	12	30
Total Gross Profit	0.09	0.34	6.95	16	162	34	58	65	84	83
Total Revenue	0.09	0.08	7.80	16	166	44	63	73	84	108
Operating Revenue	0.09	0.08	7.80	16	166	44	63	73	84	108
Total Cost of Revenue	0.00	-0.26	0.86	0.00	3.51	9.77	5.44	8.30	0.00	25
Total Operating Expenses	35	78	44	61	48	47	67	56	71	53
Selling, General & Admin Expense	14	48	28	31	33	31	35	39	42	39
Research & Development Expense	21	30	16	28	15	17	33	18	20	24
Total Other Income / (Expense), net	-0.86	-0.93	-2.24	-2.94	-0.85	-1.54	-1.41	-2.27	-8.17	-4.50
Interest Expense	1.65	2.86	2.84	3.63	3.71	2.43	2.29	3.98	11	6.93
Other Income / (Expense), net	0.79	1.93	0.60	0.69	2.86	0.89	0.88	1.71	2.67	2.44
Income Tax Expense	-	-	0.00	0.00	0.00	0.39	0.03	-0.33	0.39	2.12
Basic Earnings per Share	($0.26)	($0.58)	($0.28)	($0.34)	$0.80	($0.09)	($0.07)	$0.05	$0.03	$0.15
Weighted Average Basic Shares Outstanding	135.33M	135.41M	140.31M	141.50M	142.87M	141.96M	146.21M	144.73M	145.10M	145.32M
Weighted Average Diluted Shares Outstanding	135.33M	135.41M	149.40M	141.50M	155.87M	148.51M	154.54M	159.42M	160.71M	160.34M
Weighted Average Basic & Diluted Shares Outstanding	145.34M	146.36M	149.40M	150.98M	151.41M	154.42M	154.54M	154.82M	155.67M	157.07M

This table details how cash moves in and out of TG Therapeutics' business through operations, investing, and financing, using annual figures. All values are USD millions unless otherwise specified.

Metric	2015	2016	2017	2018	2019	2020	2021	2022	2023	2024
Net Change in Cash & Equivalents	-0.65	-30	32	-14	71	441	-255	-197	-9.36	87
Net Cash From Operating Activities	-45	-63	-94	-129	-133	-215	-296	-176	-31	-41
Net Cash From Continuing Operating Activities	-45	-62	-94	-129	-133	-215	-296	-176	-31	-41
Net Income / (Loss) Continuing Operations	-63	-78	-118	-173	-173	-279	-348	-224	13	23
Consolidated Net Income / (Loss)	-63	-78	-118	-173	-173	-279	-348	-224	13	23
Depreciation Expense	0.02	0.06	0.08	0.09	0.10	0.16	0.28	0.30	0.21	0.07
Amortization Expense	0.54	0.46	0.19	0.02	0.70	1.11	1.81	1.73	0.35	-4.78
Non-Cash Adjustments To Reconcile Net Income	16	5.33	16	17	14	83	63	45	38	50
Changes in Operating Assets and Liabilities, net	2.07	11	8.44	28	25	-20	-12	0.69	-82	-109
Net Cash From Investing Activities	-25	27	-8.21	1.18	-0.72	-25	-0.33	-20	-51	-1.04
Net Cash From Continuing Investing Activities	-25	27	-8.21	1.18	-0.72	-25	-0.33	-20	-51	-1.04
Purchase of Property, Plant & Equipment	-0.04	-0.34	-0.00	-0.09	-0.13	-0.36	-0.40	-0.01	0.00	-0.05
Purchase of Investments	-49	-15	-28	-31	-30	-67	-56	-107	-147	-312
Sale and/or Maturity of Investments	24	42	20	33	29	43	56	87	96	311
Net Cash From Financing Activities	69	5.02	134	114	204	680	41	-0.39	73	129
Net Cash From Continuing Financing Activities	69	5.02	134	114	204	680	41	-0.39	73	129
Repayment of Debt	-	-0.01	-	0.00	-0.80	0.00	-1.02	-0.98	-0.13	-0.89
Repurchase of Common Equity	-	-	-	-	-	-	-	0.00	0.00	-8.76
Issuance of Debt	0.10	-	0.00	0.00	30	0.00	70	0.00	25	245
Issuance of Common Equity	-	-	-	0.00	-	-	2.22	0.00	46	0.00
Other Financing Activities, net	69	5.03	134	114	175	680	-30	0.58	1.53	-107
Cash Interest Paid	-	-	-	-	-	-	3.47	5.45	8.77	18
Cash Income Taxes Paid	-	-	-	-	-	-	-	0.00	0.00	0.50

This table details how cash moves in and out of TG Therapeutics' business through operations, investing, and financing, using quarterly figures. All values are USD millions unless otherwise specified.

Metric	Q3 2022	Q4 2022	Q1 2023	Q2 2023	Q3 2023	Q4 2023	Q1 2024	Q2 2024	Q3 2024	Q4 2024
Net Change in Cash & Equivalents	-37	-7.55	-41	36	54	-58	-17	7.44	113	-16
Net Cash From Operating Activities	-34	-24	-60	-42	84	-13	-8.21	5.54	-12	-26
Net Cash From Continuing Operating Activities	-34	-24	-60	-42	84	-13	-8.21	5.54	-12	-26
Net Income / (Loss) Continuing Operations	-36	-78	-39	-48	114	-14	-11	6.88	3.88	23
Consolidated Net Income / (Loss)	-36	-78	-39	-48	114	-14	-11	6.88	3.88	23
Depreciation Expense	0.08	0.07	0.07	0.03	0.07	0.04	0.03	0.02	0.01	0.01
Amortization Expense	0.36	0.36	0.21	0.51	0.48	-0.84	-0.98	-1.11	-1.35	-1.34
Non-Cash Adjustments To Reconcile Net Income	8.21	35	6.78	14	7.56	9.46	9.52	10	17	13
Changes in Operating Assets and Liabilities, net	-7.33	19	-28	-8.77	-38	-7.46	-6.07	-11	-32	-61
Net Cash From Investing Activities	-2.99	16	-6.17	31	-30	-45	-9.26	1.77	-9.33	16
Net Cash From Continuing Investing Activities	-2.99	16	-6.17	31	-30	-45	-9.26	1.77	-9.33	16
Purchase of Property, Plant & Equipment	-0.00	-0.00	-	-	-	-	-	-	-	-0.02
Purchase of Investments	-31	-4.00	-22	-	-56	-68	-83	-70	-102	-58
Sale and/or Maturity of Investments	28	20	16	31	26	24	73	71	92	74
Net Cash From Financing Activities	0.28	0.05	25	47	0.42	-0.00	0.01	0.14	134	-6.07
Net Cash From Continuing Financing Activities	0.28	0.05	25	47	0.42	-0.00	0.01	0.14	134	-6.07
Repayment of Debt	0.98	-0.98	-0.13	-	-	-	0.00	-	-108	108
Repurchase of Common Equity	-	-	-	-	-	-	-	-	-	-6.61
Other Financing Activities, net	-0.70	1.02	0.36	0.75	0.42	-	0.01	0.14	0.20	-107
Cash Interest Paid	-	1.54	1.75	2.18	-	4.84	2.45	2.49	7.11	6.42

This table presents TG Therapeutics' assets and liabilities at the end of each period, using annual balance sheet data. All values are USD millions unless otherwise specified.

Metric	2015	2016	2017	2018	2019	2020	2021	2022	2023	2024
Total Assets	113	55	97	84	163	626	380	194	330	578
Total Current Assets	87	51	93	79	149	612	331	168	318	566
Cash & Equivalents	55	25	57	42	113	553	299	102	93	180
Short-Term Investments	22	20	28	27	28	52	16	59	125	131
Accounts Receivable	-	-	-	-	-	0.00	1.39	0.00	51	129
Inventories, net	-	-	-	-	-	-	-	0.00	40	110
Other Current Assets	0.31	0.22	0.44	0.44	0.61	1.08	2.88	2.36	9.52	16
Plant, Property, & Equipment, net	0.05	0.33	0.25	0.25	0.28	0.48	0.60	0.31	0.00	0.00
Total Noncurrent Assets	27	3.59	3.82	4.33	14	13	48	25	12	11
Long-Term Investments	25	-	-	-	-	0.00	36	12	0.00	0.81
Other Noncurrent Operating Assets	0.17	0.16	-	1.24	11	11	9.89	10	12	11
Total Liabilities & Shareholders' Equity	113	55	97	84	163	626	380	194	330	578
Total Liabilities	12	19	30	60	124	106	142	135	169	355
Total Current Liabilities	11	17	28	39	84	88	65	53	54	91
Accounts Payable	9.35	15	26	36	30	37	51	42	38	58
Current Deferred Revenue	0.15	0.15	0.15	-	-	-	-	-	0.15	11
Current Employee Benefit Liabilities	0.82	1.39	1.80	2.26	3.80	8.46	10	8.43	12	15
Other Current Liabilities	-	-	-	0.22	51	20	2.95	2.75	2.93	5.78
Total Noncurrent Liabilities	1.37	2.04	2.43	21	40	19	77	82	115	265
Long-Term Debt	-	-	-	0.00	29	7.72	67	71	100	244
Noncurrent Deferred Revenue	1.37	2.04	2.43	2.38	0.76	0.61	0.46	0.31	6.02	12
Other Noncurrent Operating Liabilities	-	-	0.00	18	10	10	9.85	10	9.23	8.13
Commitments & Contingencies	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Total Equity & Noncontrolling Interests	102	36	67	24	39	519	237	59	161	222
Total Preferred & Common Equity	102	36	67	24	39	519	237	59	161	222
Total Common Equity	102	36	67	24	39	519	237	59	161	222
Common Stock	260	272	422	553	740	1,500	1,566	1,586	1,713	1,761
Retained Earnings	-158	-236	-355	-528	-701	-981	-1,329	-1,527	-1,553	-1,529
Treasury Stock	-0.23	-0.23	-0.23	-0.23	-0.23	-0.23	-0.23	-0.23	-0.23	-8.99

This table presents TG Therapeutics' assets and liabilities at the end of each period, using quarterly balance sheet data. All values are USD millions unless otherwise specified.

Metric	Q3 2022	Q1 2023	Q2 2023	Q3 2023	Q1 2024	Q2 2024	Q3 2024
Total Assets	218	197	221	331	373	401	586
Total Current Assets	183	185	209	319	361	389	574
Cash & Equivalents	110	61	97	151	75	83	196
Short-Term Investments	66	78	48	78	134	134	145
Accounts Receivable	0.00	8.62	17	39	65	84	116
Inventories, net	-	27	30	34	78	81	85
Other Current Assets	2.95	4.46	11	12	8.10	7.05	33
Plant, Property, & Equipment, net	0.38	0.24	0.21	0.13	0.07	0.00	0.00
Total Noncurrent Assets	35	12	12	12	13	12	12
Long-Term Investments	22	0.00	0.00	0.00	1.32	0.95	1.13
Other Noncurrent Operating Assets	10	9.97	9.75	9.55	9.20	11	11
Total Liabilities & Shareholders' Equity	218	197	221	331	373	401	586
Total Liabilities	117	170	180	166	213	224	394
Total Current Liabilities	36	63	73	58	100	109	125
Accounts Payable	30	57	63	40	87	93	101
Current Deferred Revenue	-	-	-	6.90	3.37	3.37	9.09
Current Employee Benefit Liabilities	4.30	3.22	6.64	8.34	3.60	6.35	10
Other Current Liabilities	2.42	2.77	3.08	2.70	5.45	5.47	4.53
Total Noncurrent Liabilities	81	107	108	109	114	115	269
Long-Term Debt	70	97	98	99	101	103	244
Noncurrent Deferred Revenue	0.34	0.27	0.23	0.19	3.24	3.74	16
Other Noncurrent Operating Liabilities	11	10	9.81	9.52	8.96	8.70	8.42
Commitments & Contingencies	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Total Equity & Noncontrolling Interests	100	27	40	165	160	178	192
Total Preferred & Common Equity	100	27	40	165	160	178	192
Total Common Equity	100	27	40	165	160	178	192
Common Stock	1,575	1,594	1,655	1,665	1,685	1,734	1,747
Retained Earnings	-1,474	-1,566	-1,614	-1,500	-1,525	-1,556	-1,553
Treasury Stock	-	-0.23	-0.23	-0.23	-0.23	-0.23	-2.38

This table displays calculated financial ratios and metrics derived from TG Therapeutics' official financial filings.

Metric	2015	2016	2017	2018	2019	2020	2021	2022	2023	2024
Growth Metrics	-	-	-	-	-	-	-	-	-	-
Revenue Growth	0.00%	-0.25%	0.00%	0.00%	0.00%	0.00%	4,300.66%	-58.36%	8,290.02%	40.80%
EBITDA Growth	-12.46%	-24.74%	-50.36%	-46.98%	3.31%	-62.95%	-25.24%	37.83%	112.40%	71.15%
EBIT Growth	-13.05%	-24.48%	-49.70%	-46.73%	2.91%	-62.93%	-25.42%	37.62%	112.02%	93.25%
NOPAT Growth	-13.39%	-24.99%	-50.33%	-46.91%	3.06%	-61.84%	-26.02%	36.68%	113.10%	91.37%
Net Income Growth	-12.85%	-24.31%	-51.40%	-46.43%	0.35%	-61.61%	-24.60%	35.70%	105.66%	84.52%
EPS Growth	15.85%	-15.94%	-19.38%	-20.42%	14.78%	-23.47%	-8.68%	37.26%	105.45%	66.67%
Operating Cash Flow Growth	-27.47%	-41.31%	-48.46%	-37.51%	-3.01%	-61.52%	-37.82%	40.41%	82.17%	-28.98%
Free Cash Flow Firm Growth	5.12%	-10.90%	-59.17%	-28.14%	5.29%	-130.41%	-21.11%	38.99%	56.15%	-9.06%
Invested Capital Growth	-199.89%	-829.77%	-90.76%	-146.74%	-62.38%	22.88%	19.23%	2.25%	197.19%	259.49%
Revenue Q/Q Growth	0.00%	-0.25%	0.19%	0.00%	0.00%	0.00%	51.82%	-44.58%	23.13%	24.25%
EBITDA Q/Q Growth	1.88%	-7.40%	-5.45%	-186.50%	38.53%	-22.07%	-1.52%	7.22%	337.16%	2,967.83%
EBIT Q/Q Growth	1.72%	-7.27%	-5.48%	-185.42%	38.36%	-22.01%	-1.58%	7.23%	299.67%	779.36%
NOPAT Q/Q Growth	1.68%	-8.80%	-6.27%	-178.61%	38.29%	-21.72%	-1.82%	6.59%	250.94%	10,936.45%
Net Income Q/Q Growth	1.85%	-8.40%	-6.46%	-178.92%	37.24%	-21.08%	-1.49%	6.23%	148.92%	262.79%
EPS Q/Q Growth	9.80%	-8.11%	1.55%	-158.43%	42.52%	-15.24%	1.50%	6.78%	0.00%	0.00%
Operating Cash Flow Q/Q Growth	4.70%	-9.89%	-3.61%	-16.96%	7.10%	-11.22%	-13.38%	26.35%	25.34%	-44.26%
Free Cash Flow Firm Q/Q Growth	7.55%	-2.05%	-6.65%	-224.80%	39.01%	-19.47%	-6.40%	19.16%	10.02%	-22.64%
Invested Capital Q/Q Growth	-254.39%	-121.03%	-43.17%	-65.27%	-2.97%	-4.36%	15.78%	-63.15%	24.90%	64.62%
Profitability Metrics	-	-	-	-	-	-	-	-	-	-
Gross Margin	100.00%	100.00%	100.00%	100.00%	100.00%	100.00%	88.19%	100.00%	93.95%	88.30%
EBITDA Margin	-41,062.67%	-51,351.32%	-77,212.50%	-113,487.50%	-109,728.29%	-178,804.61%	-5,088.53%	-7,597.59%	11.23%	13.65%
Operating Margin	-41,461.87%	-51,953.29%	-78,100.00%	-114,736.84%	-111,220.39%	-179,996.05%	-5,154.28%	-7,838.99%	8.83%	12.74%
EBIT Margin	-41,424.65%	-51,694.74%	-77,388.82%	-113,555.92%	-110,252.63%	-179,639.47%	-5,119.79%	-7,670.41%	10.99%	15.08%
Profit (Net Income) Margin	-41,310.04%	-51,482.24%	-77,944.74%	-114,132.89%	-113,730.92%	-183,803.29%	-5,204.08%	-8,036.34%	5.42%	7.11%
Tax Burden Percent	100.00%	100.00%	100.00%	100.00%	100.00%	100.00%	100.00%	100.00%	97.01%	91.36%
Interest Burden Percent	99.72%	99.59%	100.72%	100.51%	103.15%	102.32%	101.65%	104.77%	50.87%	51.58%
Effective Tax Rate	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	2.99%	8.64%
Return on Invested Capital (ROIC)	-8,197,592.44%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	38.67%
ROIC Less NNEP Spread (ROIC-NNEP)	-8,197,571.83%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	54.83%
Return on Net Nonoperating Assets (RNNOA)	8,197,523.14%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	-26.46%
Return on Equity (ROE)	-69.30%	-113.87%	-230.36%	-381.16%	-551.85%	-100.14%	-92.03%	-151.36%	11.57%	12.21%
Cash Return on Invested Capital (CROIC)	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	-156.46%	-74.27%
Operating Return on Assets (OROA)	-63.05%	-93.40%	-154.61%	-190.73%	-135.90%	-69.24%	-68.13%	-74.54%	9.82%	10.94%
Return on Assets (ROA)	-62.88%	-93.02%	-155.72%	-191.70%	-140.19%	-70.85%	-69.26%	-78.09%	4.84%	5.15%
Return on Common Equity (ROCE)	-69.30%	-113.87%	-230.36%	-381.16%	-551.85%	-100.14%	-92.03%	-151.36%	11.57%	12.21%
Return on Equity Simple (ROE_SIMPLE)	-61.97%	-218.17%	-176.85%	-721.76%	-447.68%	-53.79%	-146.78%	-382.02%	7.90%	10.52%
Net Operating Profit after Tax (NOPAT)	-44	-55	-83	-122	-118	-192	-241	-153	20	38
NOPAT Margin	-29,023.31%	-36,367.30%	-54,670.00%	-80,315.79%	-77,854.28%	-125,997.24%	-3,608.00%	-5,487.30%	8.57%	11.64%
Net Nonoperating Expense Percent (NNEP)	-20.61%	-31.05%	-54.19%	-66.72%	-60.47%	-25.58%	-24.88%	-36.83%	-6.67%	-16.15%
Return On Investment Capital (ROIC_SIMPLE)	-	-	-	-	-	-	-	-117.81%	7.68%	8.21%
Cost of Revenue to Revenue	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	11.81%	0.00%	6.05%	11.70%
SG&A Expenses to Revenue	10,254.02%	6,505.92%	10,744.08%	9,974.34%	9,886.18%	70,953.95%	1,914.94%	3,428.51%	52.51%	46.90%
R&D to Revenue	31,307.86%	45,547.37%	67,455.92%	104,862.50%	101,434.21%	109,142.11%	3,327.54%	4,500.97%	32.61%	28.66%
Operating Expenses to Revenue	41,561.87%	52,053.29%	78,200.00%	114,836.84%	111,320.39%	180,096.05%	5,242.47%	7,938.99%	85.12%	75.56%
Earnings before Interest and Taxes (EBIT)	-63	-79	-118	-173	-168	-273	-342	-214	26	50
Earnings before Interest, Taxes, Depreciation and Amortization (EBITDA)	-63	-78	-117	-173	-167	-272	-340	-212	26	45
Valuation Ratios	-	-	-	-	-	-	-	-	-	-
Price to Book Value (P/BV)	6.17	7.10	8.65	14.14	28.62	13.17	11.45	29.35	16.11	21.07
Price to Tangible Book Value (P/TBV)	6.22	7.26	8.75	14.63	29.22	13.19	11.49	29.75	16.11	21.07
Price to Revenue (P/Rev)	4,111.80	1,674.34	3,811.50	2,236.04	7,270.60	45,000.79	406.03	617.38	11.07	14.24
Price to Earnings (P/E)	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	204.08	200.38
Dividend Yield	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Earnings Yield	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.49%	0.50%
Enterprise Value to Invested Capital (EV/IC)	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	57.26	29.80
Enterprise Value to Revenue (EV/Rev)	3,442.30	1,379.50	3,255.00	1,782.75	6,537.28	41,214.40	363.79	580.41	10.57	14.04
Enterprise Value to EBITDA (EV/EBITDA)	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	94.07	102.82
Enterprise Value to EBIT (EV/EBIT)	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	96.14	93.07
Enterprise Value to NOPAT (EV/NOPAT)	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	123.33	120.56
Enterprise Value to Operating Cash Flow (EV/OCF)	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Enterprise Value to Free Cash Flow (EV/FCFF)	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Leverage & Solvency	-	-	-	-	-	-	-	-	-	-
Debt to Equity	0.00	0.00	0.00	0.00	0.75	0.06	0.29	1.21	0.62	1.10
Long-Term Debt to Equity	0.00	0.00	0.00	0.00	0.75	0.01	0.28	1.21	0.62	1.10
Financial Leverage	-1.00	-1.08	-1.27	-1.69	-2.88	-1.23	-1.13	-1.30	-1.01	-0.48
Leverage Ratio	1.10	1.22	1.48	1.99	3.94	1.41	1.33	1.94	2.39	2.37
Compound Leverage Factor	1.10	1.22	1.49	2.00	4.06	1.45	1.35	2.03	1.21	1.22
Debt to Total Capital	0.21%	0.19%	0.19%	0.00%	42.86%	5.44%	22.22%	54.84%	38.42%	52.36%
Short-Term Debt to Total Capital	0.21%	0.19%	0.19%	0.00%	0.00%	4.04%	0.32%	0.00%	0.00%	0.00%
Long-Term Debt to Total Capital	0.00%	0.00%	0.00%	0.00%	42.86%	1.40%	21.90%	54.84%	38.42%	52.36%
Preferred Equity to Total Capital	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Noncontrolling Interests to Total Capital	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Common Equity to Total Capital	99.79%	99.81%	99.81%	100.00%	57.14%	94.56%	77.78%	45.16%	61.58%	47.64%
Debt to EBITDA	0.00	0.00	0.00	0.00	-0.17	-0.11	-0.20	-0.34	3.82	5.44
Net Debt to EBITDA	1.63	0.57	0.72	0.00	0.67	2.12	0.83	0.49	-4.47	-1.50
Long-Term Debt to EBITDA	0.00	0.00	0.00	0.00	-0.17	-0.03	-0.20	-0.34	3.82	5.44
Debt to NOPAT	0.00	0.00	0.00	0.00	-0.24	-0.16	-0.28	-0.47	5.00	6.38
Net Debt to NOPAT	2.31	0.81	1.02	0.00	0.94	3.01	1.17	0.67	-5.86	-1.76
Long-Term Debt to NOPAT	0.00	0.00	0.00	0.00	-0.24	-0.04	-0.28	-0.47	5.00	6.38
Altman Z-Score	28.61	-1.95	3.16	-11.66	-3.61	35.98	4.42	-6.32	4.51	6.05
Noncontrolling Interest Sharing Ratio	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Liquidity Ratios	-	-	-	-	-	-	-	-	-	-
Current Ratio	8.25	3.01	3.34	2.03	1.77	6.99	5.06	3.16	5.92	6.25
Quick Ratio	7.35	2.66	3.03	1.77	1.66	6.91	4.84	3.04	5.00	4.85
Cash Flow Metrics	-	-	-	-	-	-	-	-	-	-
Free Cash Flow to Firm (FCFF)	-42	-47	-74	-95	-90	-208	-252	-154	-67	-74
Operating Cash Flow to CapEx	-105,858.47%	-18,358.43%	-4,688,000.00%	-143,250.00%	-101,378.63%	-60,085.99%	-73,724.19%	-1,258,357.14%	0.00%	-90,037.78%
Free Cash Flow to Firm to Interest Expense	0.00	0.00	-88.10	-108.78	-17.09	-32.89	-44.72	-15.10	-5.35	-3.06
Operating Cash Flow to Interest Expense	0.00	0.00	-110.96	-147.01	-25.12	-33.89	-52.44	-17.29	-2.49	-1.69
Operating Cash Flow Less CapEx to Interest Expense	0.00	0.00	-110.96	-147.11	-25.14	-33.95	-52.51	-17.29	-2.49	-1.69
Efficiency Ratios	-	-	-	-	-	-	-	-	-	-
Asset Turnover	0.00	0.00	0.00	0.00	0.00	0.00	0.01	0.01	0.89	0.73
Accounts Receivable Turnover	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	3.65
Inventory Turnover	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.51
Fixed Asset Turnover	4.52	0.81	0.53	0.61	0.57	0.40	12.38	6.14	0.00	0.00
Accounts Payable Turnover	0.00	0.00	0.00	0.00	0.00	0.00	0.02	0.00	0.35	0.80
Days Sales Outstanding (DSO)	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	100.00
Days Inventory Outstanding (DIO)	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	712.63
Days Payable Outstanding (DPO)	0.00	0.00	0.00	0.00	0.00	0.00	20,400.27	0.00	1,039.52	458.87
Cash Conversion Cycle (CCC)	0.00	0.00	0.00	0.00	0.00	0.00	-20,400.27	0.00	-1,039.52	353.76
Capital & Investment Metrics	-	-	-	-	-	-	-	-	-	-
Invested Capital	-1.03	-9.53	-18	-45	-73	-56	-45	-44	43	155
Invested Capital Turnover	282.45	-0.03	-0.01	0.00	0.00	0.00	-0.13	-0.06	-374.46	3.32
Increase / (Decrease) in Invested Capital	-2.05	-8.51	-8.65	-27	-28	17	11	1.02	87	112
Enterprise Value (EV)	525	210	495	271	994	6,265	2,433	1,616	2,469	4,618
Market Capitalization	627	254	579	340	1,105	6,840	2,716	1,719	2,586	4,686
Book Value per Share	$1.93	$0.66	$0.95	$0.29	$0.39	$3.95	$1.66	$0.40	$1.06	$1.43
Tangible Book Value per Share	$1.92	$0.64	$0.94	$0.28	$0.38	$3.94	$1.65	$0.40	$1.06	$1.43
Total Capital	102	36	67	24	68	549	305	130	261	467
Total Debt	0.21	0.07	0.13	0.00	29	30	68	71	100	244
Total Long-Term Debt	0.00	0.00	0.00	0.00	29	7.72	67	71	100	244
Net Debt	-102	-45	-85	-69	-111	-576	-283	-103	-117	-67
Capital Expenditures (CapEx)	0.04	0.34	0.00	0.09	0.13	0.36	0.40	0.01	0.00	0.05
Debt-free, Cash-free Net Working Capital (DFCFNWC)	-0.67	-11	-19	-29	-76	-59	-48	-47	47	165
Debt-free Net Working Capital (DFNWC)	77	34	65	40	65	546	267	115	264	476
Net Working Capital (NWC)	76	34	65	40	65	524	266	115	264	476
Net Nonoperating Expense (NNE)	19	23	35	51	55	88	107	71	7.34	15
Net Nonoperating Obligations (NNO)	-103	-45	-85	-69	-111	-576	-283	-103	-117	-67
Total Depreciation and Amortization (D&A)	0.55	0.52	0.27	0.10	0.80	1.27	2.09	2.03	0.57	-4.71
Debt-free, Cash-free Net Working Capital to Revenue	-440.63%	-7,125.37%	-12,650.00%	-18,897.37%	-49,824.34%	-38,855.92%	-720.69%	-1,673.43%	19.99%	50.05%
Debt-free Net Working Capital to Revenue	50,240.13%	22,404.33%	43,084.87%	26,432.24%	42,567.11%	359,450.66%	3,984.99%	4,131.89%	113.08%	144.58%
Net Working Capital to Revenue	50,101.30%	22,359.02%	43,000.66%	26,432.24%	42,567.11%	344,859.21%	3,970.41%	4,131.89%	113.08%	144.58%
Earnings Adjustments	-	-	-	-	-	-	-	-	-	-
Adjusted Basic Earnings per Share	($1.38)	($1.60)	($1.91)	($2.30)	($1.96)	($2.42)	($2.63)	($1.46)	$0.09	$0.16
Adjusted Weighted Average Basic Shares Outstanding	54.10M	56.91M	75.58M	83.87M	109.40M	140.59M	142.82M	135.41M	141.96M	145.32M
Adjusted Diluted Earnings per Share	($1.38)	($1.60)	($1.91)	($2.30)	($1.96)	($2.42)	($2.63)	($1.46)	$0.09	$0.15
Adjusted Weighted Average Diluted Shares Outstanding	54.10M	56.91M	75.58M	83.87M	109.40M	140.59M	142.82M	135.41M	148.51M	160.34M
Adjusted Basic & Diluted Earnings per Share	($1.38)	($1.60)	($1.91)	($2.30)	($1.96)	($2.42)	($2.63)	$0.00	$0.00	$0.00
Adjusted Weighted Average Basic & Diluted Shares Outstanding	45.65M	49.04M	62.07M	75.47M	88.37M	115.33M	132.22M	146.36M	154.42M	157.07M
Normalized Net Operating Profit after Tax (NOPAT)	-44	-55	-83	-122	-118	-192	-241	-153	20	38
Normalized NOPAT Margin	-29,023.31%	-36,367.30%	-54,670.00%	-80,315.79%	-77,854.28%	-125,997.24%	-3,608.00%	-5,487.30%	8.57%	11.64%
Pre Tax Income Margin	-41,310.04%	-51,482.24%	-77,944.74%	-114,132.89%	-113,730.92%	-183,803.29%	-5,204.08%	-8,036.34%	5.59%	7.78%
Debt Service Ratios	-	-	-	-	-	-	-	-	-	-
EBIT to Interest Expense	0.00	0.00	-139.21	-196.81	-31.70	-43.14	-60.74	-20.96	2.04	2.07
NOPAT to Interest Expense	0.00	0.00	-98.34	-139.20	-22.38	-30.26	-42.81	-15.00	1.59	1.59
EBIT Less CapEx to Interest Expense	0.00	0.00	-139.21	-196.92	-31.72	-43.20	-60.81	-20.96	2.04	2.06
NOPAT Less CapEx to Interest Expense	0.00	0.00	-98.34	-139.30	-22.41	-30.32	-42.88	-15.00	1.59	1.59
Payout Ratios	-	-	-	-	-	-	-	-	-	-
Dividend Payout Ratio	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Augmented Payout Ratio	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	37.46%

This table displays calculated financial ratios and metrics derived from TG Therapeutics' official financial filings.

Metric	Q3 2022	Q4 2022	Q1 2023	Q2 2023	Q3 2023	Q4 2023	Q1 2024	Q2 2024	Q3 2024	Q4 2024
Growth Metrics	-	-	-	-	-	-	-	-	-	-
Revenue Growth	-95.37%	-96.51%	287.05%	2,606.06%	176,298.94%	54,183.95%	713.46%	357.05%	-49.41%	146.04%
EBITDA Growth	59.89%	17.97%	45.07%	-17.61%	450.35%	83.51%	74.14%	121.73%	-88.36%	350.48%
EBIT Growth	59.61%	18.05%	45.16%	-17.31%	444.29%	84.66%	76.94%	123.94%	-87.16%	379.29%
NOPAT Growth	58.93%	16.58%	44.68%	-14.72%	569.00%	83.90%	74.94%	129.60%	-90.15%	414.12%
Net Income Growth	58.17%	15.93%	43.15%	-17.53%	418.08%	81.63%	72.71%	114.45%	-96.59%	261.84%
EPS Growth	60.00%	17.14%	0.00%	-13.33%	380.77%	0.00%	0.00%	111.76%	-97.26%	0.00%
Operating Cash Flow Growth	48.67%	72.53%	12.79%	14.48%	342.66%	44.66%	86.30%	113.18%	-114.58%	-94.10%
Free Cash Flow Firm Growth	14.06%	27.11%	-1.82%	-34.45%	203.73%	-73.99%	-36.56%	-1.84%	-191.05%	12.26%
Invested Capital Growth	49.54%	2.25%	63.35%	80.03%	226.96%	197.19%	419.07%	1,016.85%	172.75%	259.49%
Revenue Q/Q Growth	-84.18%	-13.83%	9,533.33%	106.00%	931.57%	-73.48%	44.36%	15.74%	14.17%	28.98%
EBITDA Q/Q Growth	8.68%	-122.86%	27.36%	-20.32%	372.05%	-110.49%	24.67%	201.07%	45.79%	125.65%
EBIT Q/Q Growth	8.86%	-121.27%	27.42%	-20.87%	367.47%	-109.86%	27.64%	225.48%	43.43%	114.46%
NOPAT Q/Q Growth	10.22%	-121.78%	28.95%	-20.77%	467.05%	-107.61%	25.75%	242.66%	22.10%	142.86%
Net Income Q/Q Growth	11.58%	-119.08%	25.97%	-21.36%	339.30%	-112.65%	25.73%	164.25%	-43.60%	501.31%
EPS Q/Q Growth	13.33%	-123.08%	0.00%	0.00%	314.71%	0.00%	0.00%	0.00%	-50.00%	0.00%
Operating Cash Flow Q/Q Growth	29.77%	30.80%	-150.95%	29.88%	299.27%	-115.78%	37.87%	167.45%	-320.47%	-110.09%
Free Cash Flow Firm Q/Q Growth	-17.95%	-8.07%	-41.89%	-9.72%	191.00%	-281.27%	24.55%	18.17%	18.64%	-74.69%
Invested Capital Q/Q Growth	19.57%	-63.15%	64.44%	57.20%	611.23%	24.90%	16.74%	23.00%	52.08%	64.62%
Profitability Metrics	-	-	-	-	-	-	-	-	-	-
Gross Margin	100.00%	420.99%	89.02%	100.00%	97.88%	77.79%	91.43%	88.70%	100.00%	77.13%
EBITDA Margin	-35,888.30%	-92,816.05%	-462.73%	-270.28%	71.28%	-28.19%	-14.71%	12.85%	16.41%	28.70%
Operating Margin	-37,194.68%	-95,728.40%	-474.07%	-277.93%	69.22%	-28.39%	-14.60%	12.00%	14.82%	27.68%
EBIT Margin	-36,351.06%	-93,344.44%	-466.33%	-273.63%	70.95%	-26.37%	-13.22%	14.33%	18.00%	29.93%
Profit (Net Income) Margin	-38,104.26%	-96,877.78%	-502.78%	-296.19%	68.71%	-32.79%	-16.87%	9.36%	4.63%	21.57%
Tax Burden Percent	100.00%	100.00%	100.00%	100.00%	100.00%	102.78%	100.27%	105.01%	90.91%	91.66%
Interest Burden Percent	104.82%	103.79%	107.82%	108.25%	96.84%	120.97%	127.27%	62.22%	28.26%	78.60%
Effective Tax Rate	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	-5.01%	9.09%	8.34%
Return on Invested Capital (ROIC)	0.00%	0.00%	0.00%	0.00%	3,584.90%	0.00%	-171.19%	158.43%	55.47%	84.29%
ROIC Less NNEP Spread (ROIC-NNEP)	0.00%	0.00%	0.00%	0.00%	3,585.56%	0.00%	-165.68%	161.35%	61.97%	88.75%
Return on Net Nonoperating Assets (RNNOA)	0.00%	0.00%	0.00%	0.00%	-3,486.49%	0.00%	135.15%	-120.53%	-39.63%	-42.83%
Return on Equity (ROE)	-115.86%	-151.36%	-170.41%	-207.28%	98.41%	11.57%	-36.04%	37.90%	15.84%	41.46%
Cash Return on Invested Capital (CROIC)	0.00%	0.00%	0.00%	0.00%	-217.19%	-156.46%	-36.23%	53.45%	-93.24%	-74.27%
Operating Return on Assets (OROA)	-582.12%	-907.06%	-15.98%	-27.86%	49.05%	-23.56%	-13.40%	15.98%	10.40%	21.71%
Return on Assets (ROA)	-610.20%	-941.40%	-17.23%	-30.15%	47.51%	-29.29%	-17.10%	10.44%	2.67%	15.64%
Return on Common Equity (ROCE)	-115.86%	-151.36%	-170.41%	-207.28%	98.41%	11.57%	-36.04%	37.90%	15.84%	41.46%
Return on Equity Simple (ROE_SIMPLE)	-237.54%	0.00%	-614.42%	-434.22%	-15.72%	0.00%	25.73%	53.89%	-7.48%	0.00%
Net Operating Profit after Tax (NOPAT)	-24	-54	-26	-31	115	-8.74	-6.49	9.26	11	27
NOPAT Margin	-26,036.28%	-67,009.88%	-331.85%	-194.55%	69.22%	-19.88%	-10.22%	12.60%	13.48%	25.38%
Net Nonoperating Expense Percent (NNEP)	-4.60%	-12.55%	-10.39%	-15.56%	-0.66%	-5.15%	-5.51%	-2.92%	-6.50%	-4.46%
Return On Investment Capital (ROIC_SIMPLE)	-	-41.84%	-	-	-	-3.35%	-	-	-	5.88%
Cost of Revenue to Revenue	0.00%	-320.99%	10.98%	0.00%	2.12%	22.21%	8.57%	11.30%	0.00%	22.87%
SG&A Expenses to Revenue	15,163.83%	59,238.27%	359.71%	191.09%	19.76%	70.85%	54.48%	52.80%	50.03%	36.01%
R&D to Revenue	22,128.72%	36,586.42%	203.38%	174.95%	8.90%	39.68%	51.55%	23.90%	24.01%	22.07%
Operating Expenses to Revenue	37,294.68%	96,149.38%	563.09%	377.93%	28.66%	106.19%	106.03%	76.70%	85.18%	49.45%
Earnings before Interest and Taxes (EBIT)	-34	-76	-36	-44	118	-12	-8.39	11	15	32
Earnings before Interest, Taxes, Depreciation and Amortization (EBITDA)	-34	-75	-36	-43	118	-12	-9.34	9.44	14	31
Valuation Ratios	-	-	-	-	-	-	-	-	-	-
Price to Book Value (P/BV)	8.56	29.35	80.24	91.74	7.66	16.11	14.67	15.48	18.85	21.07
Price to Tangible Book Value (P/TBV)	8.63	29.75	82.65	93.58	7.70	16.11	14.74	15.48	18.85	21.07
Price to Revenue (P/Rev)	171.15	617.38	256.80	154.29	6.65	11.07	8.12	7.93	13.68	14.24
Price to Earnings (P/E)	0.00	0.00	0.00	0.00	0.00	204.08	57.01	28.73	0.00	200.38
Dividend Yield	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Earnings Yield	0.00%	0.00%	0.00%	0.00%	0.00%	0.49%	1.75%	3.48%	0.00%	0.50%
Enterprise Value to Invested Capital (EV/IC)	0.00	0.00	0.00	0.00	32.79	57.26	44.49	42.54	37.42	29.80
Enterprise Value to Revenue (EV/Rev)	145.74	580.41	251.76	152.33	5.96	10.57	7.74	7.60	13.31	14.04
Enterprise Value to EBITDA (EV/EBITDA)	0.00	0.00	0.00	0.00	0.00	94.07	42.24	24.87	2,406.63	102.82
Enterprise Value to EBIT (EV/EBIT)	0.00	0.00	0.00	0.00	0.00	96.14	41.71	24.34	624.37	93.07
Enterprise Value to NOPAT (EV/NOPAT)	0.00	0.00	0.00	0.00	0.00	123.33	46.77	25.88	0.00	120.56
Enterprise Value to Operating Cash Flow (EV/OCF)	0.00	0.00	0.00	0.00	0.00	0.00	110.39	38.83	0.00	0.00
Enterprise Value to Free Cash Flow (EV/FCFF)	0.00	0.00	0.00	0.00	0.00	0.00	0.00	79.59	0.00	0.00
Leverage & Solvency	-	-	-	-	-	-	-	-	-	-
Debt to Equity	0.70	1.21	3.52	2.42	0.60	0.62	0.63	0.58	1.27	1.10
Long-Term Debt to Equity	0.70	1.21	3.52	2.42	0.60	0.62	0.63	0.58	1.27	1.10
Financial Leverage	-1.20	-1.30	-1.30	-1.24	-0.97	-1.01	-0.82	-0.75	-0.64	-0.48
Leverage Ratio	1.52	1.94	2.53	2.79	2.07	2.39	3.04	2.85	2.57	2.37
Compound Leverage Factor	1.60	2.01	2.73	3.02	2.00	2.89	3.87	1.78	0.73	1.86
Debt to Total Capital	41.07%	54.84%	77.87%	70.72%	37.51%	38.42%	38.76%	36.61%	55.96%	52.36%
Short-Term Debt to Total Capital	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Long-Term Debt to Total Capital	41.07%	54.84%	77.87%	70.72%	37.51%	38.42%	38.76%	36.61%	55.96%	52.36%
Preferred Equity to Total Capital	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Noncontrolling Interests to Total Capital	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Common Equity to Total Capital	58.93%	45.16%	22.13%	29.28%	62.49%	61.58%	61.24%	63.39%	44.04%	47.64%
Debt to EBITDA	-0.31	-0.34	-0.62	-0.60	-8.94	3.82	1.91	0.97	166.77	5.44
Net Debt to EBITDA	0.56	0.49	0.28	0.29	11.77	-4.47	-2.07	-1.09	-66.95	-1.50
Long-Term Debt to EBITDA	-0.31	-0.34	-0.62	-0.60	-8.94	3.82	1.91	0.97	166.77	5.44
Debt to NOPAT	-0.43	-0.47	-0.85	-0.83	-7.46	5.00	2.12	1.01	-690.69	6.38
Net Debt to NOPAT	0.78	0.67	0.38	0.40	9.82	-5.86	-2.29	-1.14	277.25	-1.76
Long-Term Debt to NOPAT	-0.43	-0.47	-0.85	-0.83	-7.46	5.00	2.12	1.01	-690.69	6.38
Altman Z-Score	-4.76	-3.96	-3.16	2.30	0.90	4.14	2.43	3.73	3.26	5.95
Noncontrolling Interest Sharing Ratio	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Liquidity Ratios	-	-	-	-	-	-	-	-	-	-
Current Ratio	5.02	3.16	2.93	2.87	5.53	5.92	3.62	3.58	4.59	6.25
Quick Ratio	4.83	3.04	2.35	2.23	4.65	5.00	2.76	2.77	3.65	4.85
Cash Flow Metrics	-	-	-	-	-	-	-	-	-	-
Free Cash Flow to Firm (FCFF)	-51	-55	-53	-58	53	-96	-73	-59	-48	-84
Operating Cash Flow to CapEx	-862,375.00%	-795,666.67%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	-122,100.00%
Free Cash Flow to Firm to Interest Expense	-31.05	-19.32	-18.69	-16.08	14.29	-39.58	-31.73	-14.94	-4.46	-12.18
Operating Cash Flow to Interest Expense	-20.93	-8.34	-21.06	-11.58	22.54	-5.43	-3.59	1.39	-1.13	-3.70
Operating Cash Flow Less CapEx to Interest Expense	-20.93	-8.34	-21.06	-11.58	22.54	-5.43	-3.59	1.39	-1.13	-3.70
Efficiency Ratios	-	-	-	-	-	-	-	-	-	-
Asset Turnover	0.02	0.01	0.03	0.10	0.69	0.89	1.01	1.11	0.58	0.73
Accounts Receivable Turnover	0.00	0.00	1.80	2.74	0.00	0.00	7.86	6.86	3.42	3.65
Inventory Turnover	0.00	0.00	0.00	0.00	0.00	0.00	0.36	0.48	0.40	0.51
Fixed Asset Turnover	10.30	6.14	22.47	73.67	745.67	0.00	1,909.79	0.00	0.00	0.00
Accounts Payable Turnover	0.01	0.00	0.02	0.02	0.13	0.35	0.26	0.35	0.33	0.80
Days Sales Outstanding (DSO)	0.00	0.00	202.81	133.33	0.00	0.00	46.43	53.21	106.86	100.00
Days Inventory Outstanding (DIO)	0.00	0.00	0.00	0.00	0.00	0.00	1,023.33	752.97	917.72	712.63
Days Payable Outstanding (DPO)	28,838.87	0.00	22,015.48	21,207.47	2,900.42	1,039.52	1,407.71	1,056.52	1,095.68	458.87
Cash Conversion Cycle (CCC)	-28,838.87	0.00	-21,812.67	-21,074.14	-2,900.42	-1,039.52	-337.96	-250.34	-71.10	353.76
Capital & Investment Metrics	-	-	-	-	-	-	-	-	-	-
Invested Capital	-27	-44	-16	-6.75	35	43	50	62	94	155
Invested Capital Turnover	-0.12	-0.06	-0.29	-1.19	51.79	-374.46	16.75	12.57	4.12	3.32
Increase / (Decrease) in Invested Capital	27	1.02	27	27	62	87	66	69	60	112
Enterprise Value (EV)	732	1,616	2,158	3,664	1,132	2,469	2,239	2,634	3,523	4,618
Market Capitalization	860	1,719	2,201	3,711	1,262	2,586	2,349	2,749	3,621	4,686
Book Value per Share	$0.69	$0.40	$0.19	$0.27	$1.09	$1.06	$1.04	$1.15	$1.24	$1.43
Tangible Book Value per Share	$0.69	$0.40	$0.18	$0.27	$1.09	$1.06	$1.03	$1.15	$1.24	$1.43
Total Capital	171	130	124	138	264	261	261	280	436	467
Total Debt	70	71	97	98	99	100	101	103	244	244
Total Long-Term Debt	70	71	97	98	99	100	101	103	244	244
Net Debt	-128	-103	-43	-47	-130	-117	-110	-116	-98	-67
Capital Expenditures (CapEx)	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.02
Debt-free, Cash-free Net Working Capital (DFCFNWC)	-29	-47	-18	-9.00	32	47	51	63	108	165
Debt-free Net Working Capital (DFNWC)	146	115	122	136	261	264	261	280	449	476
Net Working Capital (NWC)	146	115	122	136	261	264	261	280	449	476
Net Nonoperating Expense (NNE)	11	24	13	16	0.85	5.68	4.22	2.38	7.42	4.12
Net Nonoperating Obligations (NNO)	-128	-103	-43	-47	-130	-117	-110	-116	-98	-67
Total Depreciation and Amortization (D&A)	0.44	0.43	0.28	0.54	0.55	-0.80	-0.95	-1.09	-1.34	-1.33
Debt-free, Cash-free Net Working Capital to Revenue	-586.41%	-1,673.43%	-210.02%	-37.41%	17.01%	19.99%	17.67%	18.24%	40.75%	50.05%
Debt-free Net Working Capital to Revenue	2,914.93%	4,131.89%	1,419.82%	565.05%	137.76%	113.08%	90.17%	80.90%	169.55%	144.58%
Net Working Capital to Revenue	2,914.93%	4,131.89%	1,419.82%	565.05%	137.76%	113.08%	90.17%	80.90%	169.55%	144.58%
Earnings Adjustments	-	-	-	-	-	-	-	-	-	-
Adjusted Basic Earnings per Share	($0.26)	($0.58)	($0.28)	($0.34)	$0.80	($0.09)	($0.07)	$0.05	$0.03	$0.15
Adjusted Weighted Average Basic Shares Outstanding	135.33M	135.41M	140.31M	141.50M	142.87M	141.96M	146.21M	144.73M	145.10M	145.32M
Adjusted Diluted Earnings per Share	($0.26)	($0.58)	($0.28)	($0.34)	$0.73	$0.00	$0.00	$0.04	$0.02	$0.00
Adjusted Weighted Average Diluted Shares Outstanding	135.33M	135.41M	140.31M	141.50M	155.87M	148.51M	154.54M	159.42M	160.71M	160.34M
Adjusted Basic & Diluted Earnings per Share	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00
Adjusted Weighted Average Basic & Diluted Shares Outstanding	145.34M	146.36M	149.40M	150.98M	151.41M	154.42M	154.54M	154.82M	155.67M	157.07M
Normalized Net Operating Profit after Tax (NOPAT)	-24	-54	-26	-31	80	-8.74	-6.49	6.17	11	27
Normalized NOPAT Margin	-26,036.28%	-67,009.88%	-331.85%	-194.55%	48.46%	-19.88%	-10.22%	8.40%	13.48%	25.38%
Pre Tax Income Margin	-38,104.26%	-96,877.78%	-502.78%	-296.19%	68.71%	-31.90%	-16.82%	8.92%	5.09%	23.53%
Debt Service Ratios	-	-	-	-	-	-	-	-	-	-
EBIT to Interest Expense	-20.73	-26.42	-12.79	-12.13	31.68	-4.77	-3.67	2.65	1.39	4.67
NOPAT to Interest Expense	-14.85	-18.97	-9.10	-8.62	30.91	-3.60	-2.84	2.33	1.04	3.96
EBIT Less CapEx to Interest Expense	-20.74	-26.42	-12.79	-12.13	31.68	-4.77	-3.67	2.65	1.39	4.67
NOPAT Less CapEx to Interest Expense	-14.85	-18.97	-9.10	-8.62	30.91	-3.60	-2.84	2.33	1.04	3.96
Payout Ratios	-	-	-	-	-	-	-	-	-	-
Dividend Payout Ratio	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Augmented Payout Ratio	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	37.46%

Frequently Asked Questions About TG Therapeutics' Financials

When does TG Therapeutics's financial year end?

According to the most recent income statement we have on file, TG Therapeutics' fiscal year ends in December. Their fiscal year 2024 ended on December 31, 2024.

How has TG Therapeutics' net income changed over the last 9 years?

Over the last 9 years, TG Therapeutics' net income changed from -$62.95 million in 2015 to $23.38 million in 2024, a change of -137.1%.

What is TG Therapeutics's operating income?

TG Therapeutics's total operating income in 2024 was $41.93 million, based on the following breakdown:

Total Gross Profit: $290.52 million
Total Operating Expenses: $248.59 million

How has TG Therapeutics revenue changed over the last 9 years?

Over the last 9 years, TG Therapeutics' total revenue changed from $152.38 thousand in 2015 to $329.00 million in 2024, a change of 215,808.8%.

How much debt does TG Therapeutics have?

TG Therapeutics' total liabilities were at $355.33 million at the end of 2024, a 110.1% increase from 2023, and a 2,886.0% increase since 2015.

How much cash does TG Therapeutics have?

In the past 9 years, TG Therapeutics' cash and equivalents has ranged from $25.03 million in 2016 to $553.44 million in 2020, and is currently $179.89 million as of their latest financial filing in 2024.

How has TG Therapeutics' book value per share changed over the last 9 years?

Over the last 9 years, TG Therapeutics' book value per share changed from 1.93 in 2015 to 1.43 in 2024, a change of -26.1%.

Related Companies

This page (NASDAQ:TGTX) was last updated on 4/24/2025 by MarketBeat.com Staff

From Our Partners

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

TG Therapeutics (TGTX) Financials

Frequently Asked Questions About TG Therapeutics' Financials

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

TG Therapeutics (TGTX) Financials

Annual Income Statements for TG Therapeutics

Quarterly Income Statements for TG Therapeutics

Annual Cash Flow Statements for TG Therapeutics

Quarterly Cash Flow Statements for TG Therapeutics

Annual Balance Sheets for TG Therapeutics

Quarterly Balance Sheets for TG Therapeutics

Annual Metrics and Ratios for TG Therapeutics

Quarterly Metrics and Ratios for TG Therapeutics

Frequently Asked Questions About TG Therapeutics' Financials

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools